Author | Reddy et al4 | Kuck et al2 | Kuck et al1 | Al-Khatib et al5 | Sapp et al3 | Di Biase et al6 |
Name of trial | SMASH VT | VTACH | SMS | CALYPSO | VANISH | VISTA |
Sample size | 128 | 110 | 111 | 27 | 259 | 118 |
Mean age | 67 | 66 | 67 | 64 | 68 | 66 |
LVEF (%) | 31.8 | 34.0 | 31.2 | 24 | 31.2 | 32.3 |
Proportion of patients with NYHA class III/IV | 20% | NYHA IV excluded | NYHA IV excluded | 14.8% | 23.6% NYHA III NYHA IV excluded | 34% |
Control | AAD | AAD | AAD | AAD | AAD | Clinical ablation |
Intervention | Ablation | Ablation | Ablation | Ablation | Ablation | Substrate ablation |
Length of follow-up (months) | 22 | 24 | 28 | 6 | 28 | 12 |
Mortality | 11% (AAD) vs 9% (ablation) | 7% (AAD) vs 10% (ablation) | 19% (AAD) vs 17% (ablation) | 14% (AAD) vs 15% (ablation) | 28% (AAD) vs 27% (ablation) | 15% (C-ablation) vs 9% (S-ablation) |
Readmission (%) | 19% (AAD) vs 6% (ablation) | 55% (AAD) vs 33% (ablation) | 44% (AAD) vs 39% (ablation) | 50% (AAD) vs 38% (ablation) | 31% (AAD) vs 25% (ablation) | 32% (C-ablation) vs 12% (S-ablation) |
Quality of life | Absent | SF-36 form at 12 and 24 months | SF-36 form at 0 and 23 months | Absent | Substudy with SF-36 form, EQ-5D, HADS, ICDC at 0, 3, 6, 12 months | Absent |
AAD, antiarrhythmic drug; EQ-5D, EuroQol-5 Dimension; HADS, Hospital Anxiety and Depression Scale; ICDC, ICD Patient Concerns questionnaire; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; RCT, randomised clinical trial; SF-36, Short Form-36 questionnaire; SMS, Substrate Modification Study.